# Trevi Therapeutics, Inc.: overview TRVI · Nasdaq · CIK 1563880 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/trvi.md) · [Financials](/companies/trvi/financials.md) · [Filings](/companies/trvi/filings.md) · [Insiders](/companies/trvi/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.13)](/filings/0001193125-25-280166.md) | not reported | [(0.09)](/filings/0001193125-26-206390.md) | [(0.09)](/filings/0001193125-26-338023.md) | [(0.08)](/filings/0001193125-25-280166.md) | not reported | [(0.09)](/filings/0001193125-26-206390.md) | [(0.11)](/filings/0001193125-26-338023.md) | | Free cash flow | $m | [(9.6) d](/filings/0001193125-25-280166.md) | [(9.6) d](/filings/0001193125-26-110783.md) | not reported | not reported | [(10.9) d](/filings/0001193125-25-280166.md) | [(7.6) d](/filings/0001193125-26-110783.md) | [(16.8)](/filings/0001193125-26-206390.md) | [(17.6) d](/filings/0001193125-26-338023.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.49)](/filings/0000950170-23-008472.md) | [(0.45)](/filings/0000950170-24-034167.md) | [(0.29)](/filings/0000950170-25-041194.md) | [(0.47)](/filings/0001193125-26-110783.md) | [(0.32)](/filings/0001193125-26-110783.md) | | Free cash flow | $m | not reported | [(28.3)](/filings/0000950170-24-034167.md) | [(31.8)](/filings/0000950170-25-041194.md) | [(38.3)](/filings/0001193125-26-110783.md) | [(42.1)](/filings/0001193125-26-110783.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/trvi/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $246.6m | 13,222,228 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $234.3m | 12,562,839 | | Added +4,524,778 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $208.0m | 11,155,026 | | Added +914,840 | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $185.4m | 9,939,447 | | Reduced −100 | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $106.0m | 5,684,592 | | Added +495,504 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $103.1m | 5,530,675 | | Added +552,108 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $95.0m | 5,094,668 | | Unchanged | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $76.1m | 4,081,333 | | Added +3,080,551 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $57.8m | 3,100,000 | | Added +933,496 | | [MPM BIOIMPACT LLC](/funds/1687078.md) | 2026-06-30 | $57.3m | 3,073,577 | | Reduced −224,853 | ## Recent filings [All 536 filings](/companies/trvi/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 16:12 ET | [10-Q](/filings/0001193125-26-338023.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338023 | | 2026-08-06 | 16:08 ET | [8-K](/filings/0001193125-26-337974.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337974 | | 2026-06-04 | 16:05 ET | [8-K](/filings/0001193125-26-257365.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-257365 | | 2026-05-07 | 18:23 ET | [SCHEDULE 13D/A](/filings/0001072613-26-000382.md) | Ownership report, active investor, amended | 0001072613-26-000382 | | 2026-05-05 | 16:09 ET | [10-Q](/filings/0001193125-26-206390.md) | Quarterly report, period 2026-03-31 | 0001193125-26-206390 | | 2026-05-05 | 16:07 ET | [8-K](/filings/0001193125-26-206382.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-206382 | | 2026-04-21 | 16:00 ET | [DEF 14A](/filings/0001193125-26-166695.md) | Proxy statement, period 2026-04-21 | 0001193125-26-166695 | | 2026-04-17 | 08:06 ET | [8-K](/filings/0001193125-26-160355.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-160355 | | 2026-03-17 | 16:08 ET | [10-K](/filings/0001193125-26-110783.md) | Annual report, period 2025-12-31 | 0001193125-26-110783 | | 2026-03-17 | 16:07 ET | [8-K](/filings/0001193125-26-110767.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-110767 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-110783.md), filed Mar 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1563880 - Tickers: TRVI - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:29 ET. No prices; not investment advice.